Contraindicated (one)bortezomib will boost the stage or influence of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Robust or average CYP2C19 inhibitors might boost mavacamten systemic publicity, causing coronary heart failure on account of systolic dysfunction. B: Could possibly be satisfactory. Either animal reports exhibit no hazard but human experiments https://alexandreb332oam5.livebloggs.com/profile